COMPASS PATHWAYS PLC -

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

26 май 2023 16:00:00 Источник Nasdaq GlobeNewswire

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

26 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

11 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

03 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

American Medical Association to Issue First New Code for Psychedelic Therapies

02 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference

10 апр 2023 10:10:13 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

02 мар 2023 10:23:22 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

24 фев 2023 12:01:00 Источник Nasdaq GlobeNewswire

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

08 дек 2022 04:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

28 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

03 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

03 ноя 2022 06:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

26 окт 2022 16:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

12 окт 2022 11:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

04 окт 2022 09:05:40 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

19 сен 2022 16:01:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in three upcoming investor events

01 сен 2022 08:06:21 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

04 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

02 авг 2022 16:05:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

28 июл 2022 04:00:00 Источник Nasdaq GlobeNewswire